US › Healthcare

Agenus Inc (AGEN)

US · Healthcare · Biotechnology

$7.22+0.14%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$34.5M

Revenue YoY

+34.4%

Net profit

$-550,000

EPS

$-0.01

EPS estimate

$0.05

Net margin

-1.6%

EPS came in at -0.01 against a street estimate of 0.05 — a miss of 120.0%.

Key statistics

Market cap

$323.4M

P/E

2.4

Forward P/E

3.7

P/B

218.61

Book value

$-4.67

EPS (TTM)

$2.99

52-week high

$8.85

52-week low

$2.71

50-day MA

$6.66

200-day MA

$4.30

Beta

1.40

Analyst view

Analysts rate Agenus Inc a buy (2 buy, 3 hold, 0 sell out of 5) with an average price target of $19.50.

Shareholding

Insiders

6.23%

Institutions

46.36%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.20%
Vanguard Portfolio Management, LLC	2.66%
Siren, L.L.C.	2.36%
Marshall Wace Asset Management Ltd	1.53%
BlackRock Inc	1.21%
GlobeFlex Capital, L.P.	0.93%
Geode Capital Management, LLC	0.77%
Morgan Stanley - Brokerage Accounts	0.66%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Agenus Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.